To validate the above hypothesis, we observed the effects of gefitinib, FMD, and their combination on the phosphorylation of STAT3 in both oral cancer cell lines Cal-27 and mouse tumor tissues. This evidence concerns the gene STAT3 and lip and oral cavity carcinoma.